Business Description
Cartesian Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8162121045
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.87 | |||||
Equity-to-Asset | -0.29 | |||||
Debt-to-Equity | -0.15 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.73 | |||||
Beneish M-Score | 11.09 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.7 | |||||
3-Year EBITDA Growth Rate | -32.1 | |||||
3-Year EPS without NRI Growth Rate | -10.2 | |||||
3-Year Book Growth Rate | -153.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 42.61 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 78.93 | |||||
9-Day RSI | 80.99 | |||||
14-Day RSI | 81.8 | |||||
12-1 Month Momentum % | -52.37 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.78 | |||||
Quick Ratio | 4.78 | |||||
Cash Ratio | 3.34 | |||||
Days Sales Outstanding | 67.73 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.4 | |||||
Shareholder Yield % | 4.42 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -90.55 | |||||
Net Margin % | -424.47 | |||||
FCF Margin % | -119.89 | |||||
ROA % | -93.85 | |||||
ROIC % | -28.07 | |||||
ROC (Joel Greenblatt) % | -1521.71 | |||||
ROCE % | -118.56 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.17 | |||||
EV-to-EBIT | -1.86 | |||||
EV-to-EBITDA | -1.86 | |||||
EV-to-Revenue | 8.48 | |||||
EV-to-Forward-Revenue | 21 | |||||
EV-to-FCF | -7.74 | |||||
Earnings Yield (Greenblatt) % | -53.84 | |||||
FCF Yield % | -12.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cartesian Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 50.161 | ||
EPS (TTM) (€) | -49.084 | ||
Beta | -0.53 | ||
Volatility % | 49.67 | ||
14-Day RSI | 81.8 | ||
14-Day ATR (€) | 0.758885 | ||
20-Day SMA (€) | 15.2994 | ||
12-1 Month Momentum % | -52.37 | ||
52-Week Range (€) | 13.374 - 39 | ||
Shares Outstanding (Mil) | 23.89 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cartesian Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cartesian Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Cartesian Therapeutics Inc Frequently Asked Questions
What is Cartesian Therapeutics Inc(FRA:1S70)'s stock price today?
When is next earnings date of Cartesian Therapeutics Inc(FRA:1S70)?
Does Cartesian Therapeutics Inc(FRA:1S70) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |